The causes and prognostic significance of low hemoglobin levels in tumor patients

Strahlentherapie und Onkologie

Volumn 174, Issue SUPPL. 4, 1998, Pages 17-19

  Manegold, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anemia; Cytokines; Erythropoietin; Iron; Prognostic factor; Transfusion; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; CYTOSTATIC AGENT; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEMOGLOBIN DETERMINATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 0031788382     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Abels RI, Larholt KM, Krantz KD, et al. Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In: Murphy MJ, ed. Blood cell growth factors: Their present and future use in hematology and oncology. Proc Beijing Symposium. Dayton, Ohio: Alpha Medical Press, 1991:121-41.
2. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small lung cancer. J Clin Oncol 1991;9:1618-26.
3. Beguin T. Erythropoietin and the anemia of cancer. Acta Clin Belg 1996; 51:36-52.
4. Cartwright GE. The anaemia of chronic disorders. Semin Hematol 1966;3: 351-75.
5. Doweiko JP, Goldberg MA. Erythropoietin therapy in cancer patients. Oncology 1991;5:31-7.
6. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with Epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15,3:1218-34.
7. Jelkmann W, Fandrey J. Role of inflammatory cytokines in the pathophysiology of erythropoietin response. Erythropoiesis 1993;4:10-5.
8. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322: 1689-92.
9. Ohlhauser C, Bülzebruck H, Ebert W, et al. Prognostic factors for survival in inoperable non-small-cell lung cancer: A multivariate regression analysis of 456 patients with radiation therapy. Oncology 1997;20:126-31.
10. Pagel H, Fandrey J, Jelkmann W. The cytokines IL-1, DL-6 and TNF inhibit the production of erythropoietin. Molecular Biology of Hematopoiesis, 8th Symposium, July 9-13 1993, Basel (Switzerland).
11. Spivak JL. Recombinant human erythropoietin and the anaemia of cancer. Blood 1994;84:997-1004.
12. Srinivasiah J, Jacobs PC, Rozmiarek SK, et al. Studies in nonhuman primates on the pathogenesis of rh-IL-6 related anaemia. Proc ASCO 1993; 12: abstract 348.
13. Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998;77: 1996-2002.